Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8310708,half-life,"2. Plasma concentrations of R-Casodex increased slowly in all subjects to reach a peak of 559-970 ng/ml between 15 and 48 h after dosing and, thereafter, declined monoexponentially with a mean half-life of 4.2 days.",Metabolism and enantioselective pharmacokinetics of Casodex in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310708/),d,4.2,9023,DB01128,Bicalutamide
,8310708,half-life,"Plasma concentrations of S-Casodex rose rapidly to reach a peak of 32-66 ng/ml within the first 2-5 h, and then declined monoexponentially with a mean half-life of 19 h.",Metabolism and enantioselective pharmacokinetics of Casodex in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310708/),h,19,9024,DB01128,Bicalutamide
,24944160,flow rate,"Chromatographic separation was achieved with 5 mm ammonium acetate (pH 6.5)-acetonitrile (35:65, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944160/),[ml] / [min],0.60,11057,DB01128,Bicalutamide
,24944160,total run time,"Chromatographic separation was achieved with 5 mm ammonium acetate (pH 6.5)-acetonitrile (35:65, v/v) at a flow rate of 0.60 mL/min on an Atlantis dC18 column with a total run time 3.0 min.",Development of an LC-MS/MS method for determination of bicalutamide on dried blood spots: application to pharmacokinetic study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24944160/),min,3.0,11058,DB01128,Bicalutamide
,9312310,Cmax,"After fasting, plasma concentrations of (R)-bicalutamide were much higher than those of (S)-bicalutamide; the mean (R)-enantiomer Cmax (734 ng mL-1) was about nine times higher than the (S)-enantiomer value (84 ng mL-1).",The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),[ng] / [ml],734,27980,DB01128,Bicalutamide
,9312310,Cmax,"After fasting, plasma concentrations of (R)-bicalutamide were much higher than those of (S)-bicalutamide; the mean (R)-enantiomer Cmax (734 ng mL-1) was about nine times higher than the (S)-enantiomer value (84 ng mL-1).",The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),[ng] / [ml],84,27981,DB01128,Bicalutamide
,9312310,tmax,"The corresponding tmax values were 19 and 3 h for (R)- and (S)-bicalutamide, respectively.",The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),h,19,27982,DB01128,Bicalutamide
,9312310,tmax,"The corresponding tmax values were 19 and 3 h for (R)- and (S)-bicalutamide, respectively.",The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),h,3,27983,DB01128,Bicalutamide
,9312310,t1/2,Elimination of (R)-bicalutamide from plasma was monoexponential and slow (t1/2 = 5.8 d).,The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),d,5.8,27984,DB01128,Bicalutamide
,9312310,terminal t1/2,Elimination of (S)-bicalutamide was biphasic in some volunteers but monophasic in others (terminal t1/2 =1.2 d; n = 11).,The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9312310/),d,1.2,27985,DB01128,Bicalutamide
,15509184,plasma elimination half-life,It has a long plasma elimination half-life (1 week) and accumulates about 10-fold in plasma during daily administration.,Bicalutamide: clinical pharmacokinetics and metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509184/),week,1,30607,DB01128,Bicalutamide
,19362193,flow rate,"The chromatographic separation was achieved on C18 column at 35 degrees C, with a mobile phase consisting of water: acetonitrile (adjusted to pH 3.0 with 20% o-phosphoric acid) (60:40), at a flow rate of 1.0 mL min(-1).",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),[ml] / [min],1.0,37128,DB01128,Bicalutamide
,19362193,retention times,"Bicalutamide and letrozole were well separated with retention times of 10.9+/-0.2 and 5.7+/-0.2 min, respectively.",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),min,10.9,37129,DB01128,Bicalutamide
,19362193,retention times,"Bicalutamide and letrozole were well separated with retention times of 10.9+/-0.2 and 5.7+/-0.2 min, respectively.",High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19362193/),min,5.7,37130,DB01128,Bicalutamide
,8237060,Oral absorption,"Oral absorption was about 80% in rat, mouse, rabbit and dog.",Metabolism of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237060/),%,80,44342,DB01128,Bicalutamide
,8237060,plasma elimination half-life,Recovery from dog was incomplete in 4 days but consistent with the long plasma elimination half-life of 7-7.5 days.,Metabolism of Casodex in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237060/),d,7-7.5,44343,DB01128,Bicalutamide
,8237060,half-life,Casodex was eliminated from rat plasma with a half-life of 17-21 h.,Metabolism of Casodex in laboratory animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8237060/),h,17-21,44344,DB01128,Bicalutamide
,20110037,T(max),The median T(max) was 36.0 hours for both formulations.,"Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110037/),h,36.0,58743,DB01128,Bicalutamide
,20110037,t(1/2),"The mean (SD) t(1/2), C(max), and AUC(0-672h) for the reference formulation were 135.4 (28.6) hours, 933.2 (169.2) microg/L, and 215,680.1 (48,753.4) microg x h/L, respectively.","Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110037/),h,135.4,58744,DB01128,Bicalutamide
,20110037,C(max),"The mean (SD) t(1/2), C(max), and AUC(0-672h) for the reference formulation were 135.4 (28.6) hours, 933.2 (169.2) microg/L, and 215,680.1 (48,753.4) microg x h/L, respectively.","Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110037/),[μg] / [l],933.2,58745,DB01128,Bicalutamide
,20110037,AUC(0-672h),"The mean (SD) t(1/2), C(max), and AUC(0-672h) for the reference formulation were 135.4 (28.6) hours, 933.2 (169.2) microg/L, and 215,680.1 (48,753.4) microg x h/L, respectively.","Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110037/),[h·μg] / [l],"215,680.1",58746,DB01128,Bicalutamide
,9471040,half-life,"Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics.","Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9471040/),week,1,105185,DB01128,Bicalutamide
,21158211,bone age/chronological age ratio,The bone age/chronological age ratio was reduced from 2.1 (+/- 0.6) at baseline to 1.0 (+/- 0.4) (p = 0.00013).,"Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21158211/),,2.1,106338,DB01128,Bicalutamide
,21158211,bone age/chronological age ratio,The bone age/chronological age ratio was reduced from 2.1 (+/- 0.6) at baseline to 1.0 (+/- 0.4) (p = 0.00013).,"Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21158211/),,1.0,106339,DB01128,Bicalutamide
,2094606,t1/2,"The area under the plasma concentration-time curve increased linearly with dose, and Casodex was eliminated slowly from plasma (t1/2 about 6 days).",The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094606/),d,6,107718,DB01128,Bicalutamide
,2094606,plasma elimination half-life,"During daily administration, Casodex accumulates about 10-fold in plasma at all dose levels; this is consistent with its long plasma elimination half-life, estimated by curve fitting of these multiple dose data to be 7-10 days.",The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094606/),d,7-10,107719,DB01128,Bicalutamide
,2094606,Trough plasma concentrations,"Trough plasma concentrations increased linearly with dose after both single and multiple dosing, achieving mean values of 1.80, 6.89 and 9.33 micrograms/ml for the 10 mg, 30 mg and 50 mg dose levels, respectively, after 12 weeks' dosing.",The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094606/),[μg] / [ml],1.80,107720,DB01128,Bicalutamide
,2094606,Trough plasma concentrations,"Trough plasma concentrations increased linearly with dose after both single and multiple dosing, achieving mean values of 1.80, 6.89 and 9.33 micrograms/ml for the 10 mg, 30 mg and 50 mg dose levels, respectively, after 12 weeks' dosing.",The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094606/),[μg] / [ml],6.89,107721,DB01128,Bicalutamide
,2094606,Trough plasma concentrations,"Trough plasma concentrations increased linearly with dose after both single and multiple dosing, achieving mean values of 1.80, 6.89 and 9.33 micrograms/ml for the 10 mg, 30 mg and 50 mg dose levels, respectively, after 12 weeks' dosing.",The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2094606/),[μg] / [ml],9.33,107722,DB01128,Bicalutamide
,9074908,plasma half-life,"Clinical studies indicated that Casodex is orally bioavailable and well absorbed, with a plasma half-life of around 1 week.",Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074908/),week,1,117569,DB01128,Bicalutamide
,21353117,T(max),Median T(max) was 24 hours for both formulations.,"Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21353117/),h,24,121165,DB01128,Bicalutamide
,21353117,C(max),"The C(max) of the test and reference formulations was 1176.2 (191.6) and 1118.9 (209.5) μg/L, respectively.","Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21353117/),[μg] / [l],1176.2,121166,DB01128,Bicalutamide
,21353117,C(max),"The C(max) of the test and reference formulations was 1176.2 (191.6) and 1118.9 (209.5) μg/L, respectively.","Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21353117/),[μg] / [l],1118.9,121167,DB01128,Bicalutamide
,21353117,AUC(0-672),"The corresponding values for AUC(0-672) were 277,503 (66,865) and 271,961 (75,597) μg · h/L.","Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21353117/),[h·μg] / [l],"277,503",121168,DB01128,Bicalutamide
,21353117,AUC(0-672),"The corresponding values for AUC(0-672) were 277,503 (66,865) and 271,961 (75,597) μg · h/L.","Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21353117/),[h·μg] / [l],"271,961",121169,DB01128,Bicalutamide
,7483662,elimination half-life,"3. After dosing R-labelled Casodex, plasma concentrations of R-Casodex increased slowly to reach a peak of 3.50 +/- 0.05 micrograms/ml (mean +/- SEM) at 12 h and, thereafter, declined monoexponentially with an elimination half-life of 24 h.",Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7483662/),h,24,140472,DB01128,Bicalutamide
,7483662,peak,"Plasma concentrations of S-Casodex rose rapidly to reach a much lower peak of 0.97 +/- 0.06 microgram/ml at 3 h and, thereafter, declined rapidly, although there were insufficient data to determine the half-life.",Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7483662/),[μg] / [ml],0.97,140473,DB01128,Bicalutamide
,7483662,AUC0-24,R-Casodex had a much higher AUC0-24 (66 micrograms.h/ml) than S-Casodex (12 micrograms.h/ml).,Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7483662/),[h·μg] / [ml],66,140474,DB01128,Bicalutamide
,7483662,AUC0-24,R-Casodex had a much higher AUC0-24 (66 micrograms.h/ml) than S-Casodex (12 micrograms.h/ml).,Enantioselective metabolism and pharmacokinetics of Casodex in the male rat. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7483662/),[h·μg] / [ml],12,140475,DB01128,Bicalutamide
,22495777,flow rate,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid:acetonitrile, 35:65, v/v) at a flow rate of 0.5 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1°C) with a total run time of 3.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),[ml] / [min],0.5,147485,DB01128,Bicalutamide
,22495777,total run time,"Chromatographic separation was achieved using an isocratic mobile phase (0.2% formic acid:acetonitrile, 35:65, v/v) at a flow rate of 0.5 mL/min on an Atlantis dC₁₈ column (maintained at 40 ± 1°C) with a total run time of 3.0 min.",Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),min,3.0,147486,DB01128,Bicalutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,428.9,147487,DB01128,Bicalutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,269.0,147488,DB01128,Bicalutamide
,22495777,m/,The MS/MS ion transitions monitored were m/z 428.9 → 254.7 for bicalutamide and m/z 269.0 → 169.6 for IS.,Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495777/),,169.6,147489,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,72,156115,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,88,156116,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,10,156117,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,12,156118,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,100,156119,DB01128,Bicalutamide
,1796611,bioavailability,3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg.,The pharmacokinetics of Casodex in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),%,31,156120,DB01128,Bicalutamide
,1796611,terminal elimination half-lives,4. Elimination of Casodex from plasma was slow with terminal elimination half-lives of about 1 day in rat and about 6 days in dog.,The pharmacokinetics of Casodex in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),d,1,156121,DB01128,Bicalutamide
,1796611,terminal elimination half-lives,4. Elimination of Casodex from plasma was slow with terminal elimination half-lives of about 1 day in rat and about 6 days in dog.,The pharmacokinetics of Casodex in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796611/),d,6,156122,DB01128,Bicalutamide
,7500470,objective response rate,The objective response rate (modified European Organization for Research in Cancer Therapy criteria) was 70%.,"Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7500470/),%,70,157594,DB01128,Bicalutamide
,7500470,drug plasma concentration,"Mean drug plasma concentration was 8,528 +/- 2,928 ng/ml.","Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7500470/),[ng] / [ml],"8,528",157595,DB01128,Bicalutamide
,8560676,objective response rate,"The objective response rate (modified European Organization on Research and Treatment of Cancer [EORTC] criteria) was 70% (57% partial, 13% stable); 59 (39%) of 150 patients had either a > 90% decrease in prostate-specific antigen (PSA) levels or a decline to < 4 ng/mL.",Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560676/),%,70,166940,DB01128,Bicalutamide
,8560676,drug plasma concentration,"Gastrointestinal toxicity was very infrequent (diarrhea, 5%) The mean drug plasma concentration was 8528 (+/- 2928) ng/mL.",Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560676/),[ng] / [ml],8528,166941,DB01128,Bicalutamide
,12959312,Cmax,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),[ng] / [ml],750,168511,DB01128,Bicalutamide
,12959312,Cmax,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),[ng] / [ml],848,168512,DB01128,Bicalutamide
,12959312,tmax,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),h,24,168513,DB01128,Bicalutamide
,12959312,tmax,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),h,30,168514,DB01128,Bicalutamide
,12959312,t(1/2),4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),d,7.40,168515,DB01128,Bicalutamide
,12959312,t(1/2),4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),d,7.22,168516,DB01128,Bicalutamide
,12959312,AUC,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),[h·μg] / [ml],182,168517,DB01128,Bicalutamide
,12959312,AUC,4. The kinetics of (R)-Casodex were similar in subjects with and without liver disease (Cmax: 750 vs 848 ng ml(-1); tmax: 24 - 30 h; t(1/2): 7.40 vs 7.22 days; AUC: 182 vs 225 microg ml(-1) h).,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),[h·μg] / [ml],225,168518,DB01128,Bicalutamide
less,12959312,terminal phase half-life,5. The kinetics of (S)-Casodex could not be described in the majority of subjects; in the remainder the mean terminal phase half-life for both groups was less than 1 day.,The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959312/),d,1,168519,DB01128,Bicalutamide
,28743076,flow rate,"Chromatographic separation was achieved using an Atlantis C18 column with an isocratic mobile phase comprising 0.2% formic acid:acetonitrile (35:65, v/v) at a flow rate of 0.8mL/min within 2.5min.","LC-MS/MS-ESI method for simultaneous quantification of darolutamide and its active metabolite, ORM-15341 in mice plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28743076/),[ml] / [min],0.8,217454,DB01128,Bicalutamide
,8560674,plasma elimination half-life,"The S-enantiomer of bicalutamide is rapidly cleared, but the R-enantiomer has a plasma elimination half-life of about 1 week, with a tenfold plasma accumulation at all dose levels, making it suitable for a once-daily administration.",Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560674/),week,1,271981,DB01128,Bicalutamide
